Envestnet Asset Management
BIB icon

Envestnet Asset Management’s ProShares Ultra NASDAQ Biotechnology BIB Stock Holding History

Envestnet Asset Management’s Portfolio BIB Stock Details BIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-2,127
Closed -$103K – 3107
2016
Q3 		$103K Buy
2,127
+172
+9% +$8.17K ﹤0.01% 2299
2016
Q2 		$76K Sell
1,955
-607
-24% -$26.2K ﹤0.01% 2556
2016
Q1 		$105K Buy
+2,562
New +$113K ﹤0.01% 2374

Other funds holding BIB

RIA
RPG Investment Advisory Pleasanton, California $829M AUM 36.68% 1-Year Est. Return
OPPM
Opus Point Partners Management New York $55.3M AUM 7.48% 1-Year Est. Return
CIC
Chase Investment Counsel Charlottesville, Virginia $381M AUM 69.8% 1-Year Est. Return
BA
BKS Advisors Southfield, Michigan $249M AUM 14.37% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
TH
Timber Hill Greenwich, Connecticut $15.4M AUM 30.7% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return

Envestnet Asset Management's BIB Position: Q4 2016 in Review

Envestnet Asset Management sold out of ProShares Ultra NASDAQ Biotechnology (BIB) in Q4 2016, closing a stake of 2,127 shares — an estimated $103K sold.

Envestnet Asset Management first reported a position in BIB in Q1 2016 and held it in 3 quarters. The position peaked at $105K in Q1 2016. 31 funds tracked by Wall St. Rank hold BIB as of Q4 2016.

  • Envestnet Asset Management reported no remaining ProShares Ultra NASDAQ Biotechnology position as of Q4 2016 after selling out during the quarter.
  • Envestnet Asset Management sold 2,127 ProShares Ultra NASDAQ Biotechnology shares in Q4 2016, an estimated $103K.
  • Envestnet Asset Management first reported a position in ProShares Ultra NASDAQ Biotechnology in Q1 2016 and held it in 3 quarters.
  • Envestnet Asset Management's ProShares Ultra NASDAQ Biotechnology position peaked at $105K in Q1 2016.
  • 31 funds tracked by Wall St. Rank held ProShares Ultra NASDAQ Biotechnology as of Q4 2016.

Based on Envestnet Asset Management's 13F filing for Q4 2016, filed 14 Feb 2017.